{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:47:26Z","timestamp":1759042046806},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.encep.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T02:30:14Z","timestamp":1496025014000},"page":"88-90","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Relais d\u2019un antipsychotique par l\u2019aripiprazole et risque d\u2019agitation"],"prefix":"10.1016","volume":"44","author":[{"given":"B.","family":"Chaumette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2017.02.007_bib0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-10-75","article-title":"Predictors of switching antipsychotic medications in the treatment of schizophrenia","volume":"10","author":"Nyhuis","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.encep.2017.02.007_bib0090","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.encep.2017.02.007_bib0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.encep.2013.10.001","article-title":"Clinical stakes when switching from one antipsychotic to another","volume":"39","author":"Constant","year":"2013","journal-title":"Encephale"},{"key":"10.1016\/j.encep.2017.02.007_bib0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.encep.2017.02.007_bib0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JCP.0b013e318296884f","article-title":"Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial","volume":"33","author":"Cipriani","year":"2013","journal-title":"J Clin Psychopharmacol"},{"unstructured":"Research C for DE and Drug safety and availability - FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada), http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm498662.htm [Consult\u00e9 le 12\/10\/2016].","key":"10.1016\/j.encep.2017.02.007_bib0110"},{"unstructured":"Mise en garde sur l\u2019utilisation hors AMM de l\u2019aripiprazole (Abilify et g\u00e9n\u00e9riques) et sur le risque de suicide - Point d\u2019information actualis\u00e9 le 05\/04\/2016 - ANSM\u00a0: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9, http:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Mise-en-garde-sur-l-utilisation-hors-AMM-de-l-aripiprazole-Abilify-et-generiques-et-sur-le-risque-de-suicide-Point-d-Information-actualise-le-05-04-2016 [Consult\u00e9 le 12\/10\/2016].","key":"10.1016\/j.encep.2017.02.007_bib0115"},{"year":"2013","author":"Stahl","series-title":"Stahl's essential psychopharmacology: neuroscientific basis and practical applications","key":"10.1016\/j.encep.2017.02.007_bib0120"},{"key":"10.1016\/j.encep.2017.02.007_bib0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-200401000-00009","article-title":"Aripiprazole possibly worsens psychosis","volume":"19","author":"Ramaswamy","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2017.02.007_bib0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","author":"Takeuchi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.encep.2017.02.007_bib0135","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1176\/appi.ajp.2007.07020363","article-title":"Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole","volume":"164","author":"Koener","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2017.02.007_bib0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0b013e3181accfec","article-title":"Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study","volume":"29","author":"Takeuchi","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2017.02.007_bib0145","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.encep.2017.02.007_bib0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1570159X14666160606093602","article-title":"Antipsychotic induced dopamine supersensitivity psychosis: a comprehensive review","volume":"15","author":"Yin","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.encep.2017.02.007_bib0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.encep.2017.02.007_bib0080","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.euroneuro.2009.04.002","article-title":"Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study","volume":"19","author":"Pae","year":"2009","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700617300684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700617300684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T12:31:11Z","timestamp":1531139471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700617300684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0013700617300684"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2017.02.007","relation":{},"ISSN":["0013-7006"],"issn-type":[{"type":"print","value":"0013-7006"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relais d\u2019un antipsychotique par l\u2019aripiprazole et risque d\u2019agitation","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}